Impact of delayed graft function on clinical outcomes in highly sensitized patients after deceased-donor kidney transplantation

다국어 초록 (Multilingual Abstract)

Background: We investigated whether the development of delayed graft function (DGF) in pre-sensitized patients affects the clinical outcomes after deceased-donor kidney transplantation (DDKT).
Methods: The study included 709 kidney transplant recipients (KTRs) from three trans- plant centers. We divided KTRs into four subgroups (highly sensitized DGF, highly sensi- tized non-DGF, low-sensitized DGF, and low-sensitized non-DGF) according to panel re- active antibody level of 50%, or DGF development. We compared post-transplant clinical outcomes among the four subgroups.
Results: Incidence of biopsy-proven acute rejection (BPAR) was higher in two highly sensitized subgroups than in low-sensitized subgroups. It tended to be higher in highly sensitized DGF subgroups than in the highly sensitized non-DGF subgroups. In addition, the highly sensitized DGF subgroup showed the highest risk for BPAR (hazard ratio, 3.051; P=0.005) and independently predicted BPAR. Allograft function was lower in the two DGF subgroups than in the non-DGF subgroup until one month after transplantation, but thereafter it was similar. Death-censored graft loss rates and patient mortality tended to be low when DGF developed, but it did not reach statistical significance.
Conclusions: DGF development in highly sensitized patients increases the risk for BPAR in DDKT compared with patients without DGF, suggesting the need for strict monitoring and management of such cases.

참고문헌 (Reference)

1 Loupy A, "The impact of donor-specific anti-HLA antibodies on late kidney allograft failure" 8 : 348-357, 2012

2 Weiskopf D, "The aging of the immune system" 22 : 1041-1050, 2009

3 van den Hoogen MW, "Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety" 15 : 407-416, 2015

4 Vlad G, "Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival" 70 : 589-594, 2009

5 Brennan DC, "Rabbit antithymocyte globulin versus basiliximab in renal transplantation" 355 : 1967-1977, 2006

6 Jordan SC, "Presensitization : the problem and its management" 1 : 421-432, 2006

7 Yarlagadda SG, "Marked variation in the definition and diagnosis of delayed graft function : a systematic review" 23 : 2995-3003, 2008

8 Viglietti D, "Kidney allograft fibrosis after transplantation from uncontrolled circulatory death donors" 99 : 409-415, 2015

9 Tullius SG, "Kidney allocation and the aging immune response" 364 : 1369-1370, 2011

10 Ponticelli C, "Ischaemia-reperfusion injury : a major protagonist in kidney transplantation" 29 : 1134-1140, 2014

11 Shoskes DA, "Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse" 49 : 201-207, 1990

12 Meier-Kriesche HU, "Increased immunosuppressive vulnerability in elderly renal transplant recipients" 69 : 885-889, 2000

13 Dikow R, "In renal transplants with delayed graft function chemokines and chemokine receptor expression predict long-term allograft function" 90 : 771-776, 2010

14 Foster BJ, "Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipients" 14 : 876-885, 2014

15 Filippone EJ, "Humoral immune response and allograft function in kidney transplantation" 66 : 337-347, 2015

16 Wissing KM, "HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies" 85 : 411-416, 2008

17 Li K, "Expression of complement components, receptors and regulators by human dendritic cells" 48 : 1121-1127, 2011

18 Metzger RA, "Expanded criteria donors for kidney transplantation" 3 (3): 114-125, 2003

19 Vo AA, "Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab" 95 : 852-858, 2013

20 Hwang SD, "Effect of pretransplant rituximab use on posttransplant clinical outcomes in patients with high panel reactive antibody scores" 130 : 239-244, 2015

21 Lieber SR, "Effect of panel-reactive antibody in predicting crossmatch selection of cadaveric kidney recipients" 39 : 429-431, 2007

22 Shamali A, "Duration of delayed graft function and outcomes after kidney transplantation from controlled donation after circulatory death donors : a retrospective study" 32 : 635-645, 2019

23 Wehmeier C, "Donor specificity but not broadness of sensitization is associated with antibody-mediated rejection and graft loss in renal allograft recipients" 17 : 2092-2102, 2017

24 Marfo K, "Desensitization protocols and their outcome" 6 : 922-936, 2011

25 Montgomery RA, "Desensitization in HLA-incompatible kidney recipients and survival" 365 : 318-326, 2011

26 Siedlecki A, "Delayed graft function in the kidney transplant" 11 : 2279-2296, 2011

27 Wu WK, "Delayed graft function and the risk of acute rejection in the modern era of kidney transplantation" 88 : 851-858, 2015

28 Tapiawala SN, "Delayed graft function and the risk for death with a functioning graft" 21 : 153-161, 2010

29 Noël C, "Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients" 20 : 1385-1392, 2009

30 Crabtree GR, "Contingent genetic regulatory events in T lymphocyte activation" 243 : 355-361, 1989

31 van Werkhoven MB, "Complement mediated renal inflammation induced by donor brain death : role of renal C5a-C5aR interaction" 13 : 875-882, 2013

32 Eun Sung Jeong, "Comparison of clinical outcomes of deceased donor kidney transplantations, with a focus on three induction therapies" 대한이식학회 33 (33): 118-127, 2019

33 Sis B, "Banff '09 meeting report : antibody mediated graft deterioration and implementation of Banff working groups" 10 : 464-471, 2010

34 Yarlagadda SG, "Association between delayed graft function and allograft and patient survival : a systematic review and meta-analysis" 24 : 1039-1047, 2009

35 Tambur AR, "Assessing antibody strength: comparison of MFI, C1q, and titer information" 15 : 2421-2430, 2015

36 Sethi S, "Allocation of the highest quality kidneys and transplant outcomes under the new kidney allocation system" 73 : 605-614, 2019

37 Kosmoliaptsis V, "Alloantibody responses after renal transplant failure can be better predicted by donor-recipient HLA amino acid sequence and physicochemical disparities than conventional HLA matching" 16 : 2139-2147, 2016

38 Martins PN, "Age and immune response in organ transplantation" 79 : 127-132, 2005

39 Irish WD, "A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation" 10 : 2279-2286, 2010

40 Levey AS, "A new equation to estimate glomerular filtration rate" 150 : 604-612, 2009